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The Policy Research Unit in Economic Evaluation of Health and Care interventions is funded by the 
Department of Health Policy Research Programme. It is a collaboration between researchers from 
the University of Sheffield and the University of York.  
 
 
The Department of Health's Policy Research Unit in Economic Evaluation of Health and Care 
Interventions is a 7 year programme of work that started in January 2011.  The unit is led by 
Professor John Brazier (Director, University of Sheffield) and Professor Mark Sculpher (Deputy 
Director, University of York) with the aim of assisting policy makers in the Department of Health to 
improve the allocation of resources in health and social care. 
 
This is an independent report commissioned and funded by the Policy Research Programme in the 
Department of Health. The views expressed are not necessarily those of the Department. 
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Acronym Definition 
AE 
BAHNO 
Adverse events 
British Association of Head and Neck Oncologists 
DH Department of Health 
EORTC-
QLQ 
FACT 
European organisation for research and treatment of cancer core quality of life 
questionnaire 
Functional assessment of cancer therapy 
EQ-5D EuroQol 5 dimensions 
FR Future research 
HRQoL Health related quality of life   
HS Health states 
HTA Health technology assessment 
MDT Multi-disciplinary team 
NCA National Clinical Audit 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
OS Overall survival 
PFS Progression free survival 
PR Potential recommendations 
PROM(s) Patient reported outcome measure(s) 
QALY Quality adjusted life year 
R&D Research and development 
RCT Randomised controlled trial 
STA Single technology assessment 
TA Technology Appraisal 
UK 
UW-QOL 
United Kingdom 
University of Washington quality of life questionnaire 
WP Work package 
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1. BACKGROUND 
EEPRU was approached by Jason Cox (R&D Division) to prepare a programme of research to support 
the appropriateness of, and use of, patient reported outcome measures (PROMs) collected for the 
National Clinical Audit (NCA).  The EEPRU programme was informed by a Research aand 
Development (R&D) template prepared by Simon Bennett, Steve Fairman and Keith Willett at NHS 
England. 
 
The purpose of introducing PROMs into the NCA programme is to be able to 1) compare 
performance between providers and commissioners in the National Health Service (NHS), 2) 
compare the cost-effectiveness of alternative providers in delivering the specific services (i.e. linking 
outcomes and resource use), and 3) assess the cost-effectiveness of alternative interventions and 
other changes in the NHS.  The intention is to introduce PROMs across a range of conditions over the 
next 3 years commencing with 13 conditions in the 2014/15 NCA programme.  
 
The agreed research programme consists of 3 concurrent work packages (WP) as described in the 
document submitted to the DH (8
th
 November 2013).  The current document provides details on the 
objectives, methodology and results for Work Package 1 (WP1): to determine what PROMS should 
be used in the 13 health conditions specified in the 2014/15 NCA programme. 
 
2. OVERVIEW 
WP1 is split into three separate components consisting of: 
WP1.1 To examine whether the Euro-QoL 5 dimensions (EQ-5D) is appropriate in the 13 health 
conditions specified in the 2013/14 NCA programme.  
WP1.2 To identify what measure could be used when the EQ-5D is not appropriate in the 13 health 
conditions, taking into account that the proposed measure would be used to generate 
preference-based utility measures (either directly through existing preference-based weights, 
or indirectly through existing mapping functions suitable for the proposed measure). 
WP1.3 To identify the evidence required to address questions of cost-effectiveness using the NCA 
data. 
 
Each component consists of a series of reviews of the literature. 
 
This Appendix provides the detailed results for the condition head and neck cancer and should be 
read in conjunction with both the main report and the methods/search strategy appendices. 
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3. METHOD 
The full detailed methodology used is provided in Appendix A, including the search strategy, 
selection criteria for studies included, and data extraction etc.  In summary, a review of the literature 
was undertaken to assess the appropriateness of the EQ-5D in terms of classic psychometric criteria 
(WP1.1); where the EQ-5D was not considered appropriate, additional searches were undertaken to 
identify alternative measures (WP1.2); and finally, existing health technology appriasials (HTA) were 
reviewed and data requirements were compared with variables currently collected in the head and 
neck cancer audit (WP1.3).   
 
3.1 Psychometric properties (WP1.1) 
Assessments reported in the included studies were categorised according to the following 
definitions: 
 
Acceptability 
Data relating to how acceptable the measure was to the person completing it, expressed as the 
proportion of completed surveys, or the proportion of missing data. 
 
Reliability 
There are two main definitions for reliability, a) the degree to which a measure reproduces the same 
results in an unchanged population and b) the degree to which a measure reproduces the same 
results when completed by different assessors (e.g. patient and proxy report). In both cases, 
reliability can be assessed by re-testing, and calculating the correlations or difference between tests. 
In case a) the comparison may be between the same populations separated by time, where no 
change in health state was observed (as compared to an alternative condition specific or generic 
ŵĞĂƐƵƌĞ ? ? /ŶĐĂƐĞď ? ƚŚĞŵĞĂƐƵƌĞŵĂǇďĞĐŽŵƉůĞƚĞĚďǇŵƵůƚŝƉůĞƉĞŽƉůĞ  ?ƉƌŽǆŝĞƐ ?ŽŶƚŚĞƉĂƚŝĞŶƚ ?Ɛ
behalf and their responses compared with those of the patient. Where the outcome measure is 
specifically designed for self-report by patients, this test of reliability may be expected to produce 
less agreement.  
 
Construct validity 
This is an assessment of how well an instrument measures what it intends to measure. Two main 
definitions are used in this review.  
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a) Known group validity, where estimates for groups that are known to differ in a concept of interest 
are compared either qualitatively or statistically. The known groups may be defined using other 
measures, according to clinical categorisation.  
b) Convergent validity assesses the extent to which a measure correlates with other measures of the 
same or similar concepts. Correlation coefficients were considered low if <0.3, moderate if between 
0.3 and 0.5, and strong when >0.5.  
 
Responsiveness 
a) Change over time. This is an assessment of whether measurements using the instrument can 
detect a change over time, where a change is expected. This may be before and after an 
intervention, or through progression of a disease. Evidence was considered to be good where a t-
test was significant, though weaker evidence to support responsiveness was considered where there 
was a change in the expected direction, but was not statistically significant or not tested. Effect size 
(ES) and standardised response mean (SRM) were also acceptable assessments of responsiveness.  
b) Ceiling and floor effects were also considered to be indicators of responsiveness. Assessments of 
ceiling effects include the proportion of patients who score full health within a group of patients 
with known health detriments. A ceiling or floor effect can affect the sensitivity of the measure in 
detecting changes over time in patients at the extremes of the measure (for example those with 
severe disease activity and those with just minor symptoms of the condition). 
 
3.2.1 Alternative measures (WP1.2) 
Where evidence suggested the EQ-5D was not appropriate, or where no evidence was identified, 
alternative measures were reviewed. 
 
3.3 Evidence required for economic evaluations (WP1.3) 
The existing HTAs were reviewed alongside the variables currently collected in the NCA to determine 
if clinical or PROM data routinely collected in the NCAs would suffice to address questions of cost-
effectiveness, and to identify any gaps in the evidence that would be required to compare providers, 
or the cost-effectiveness of interventions or policies.   
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4. RESULTS FOR HEAD AND NECK CANCER 
4.1 Evidence of appropriateness of EQ-5D in head and neck cancer (WP1.1) 
One review was identified through experts which covered all cancers.(1)  No studies for head and 
neck cancer were found by this review. Searches were conducted in August 2010 in Longworth et 
al.(1) and an update was conducted by EEPRU in May 2014. The update searches retrieved 32 
citations. None of these studies met the inclusion criteria of WP1.1.  While two studies were 
identified in patients with brain cancer, this condition is excluded from the head and neck cancer 
NCA hence the studies are not reviewed here.   
 
As such, there does not appear to be any evidence relating to the appropriateness of the EQ-5D in 
head and neck cancer.  
 
4.2 Alternative measures in head and neck cancer (WP1.2) 
Given the lack of evidence relating to the EQ-5D in patients with head and neck cancer, searches 
were conducted to identify what other generic or condition-specific measures could be used. 
 
Seven documents were retrieved by the searches. Of these, only two related documents were 
relevant to WP1.2, both from the British Association of Head and Neck Oncologists (BAHNO).(2;3) 
Four of the remaining five were clinical guidelines and did not discuss PROMS,(4-7) and one was a 
report of a survey of patient experience, which did not include health related quality of life (HRQoL) 
outcomes.(8) 
 
The two related documents from BAHNO comprise a multidisciplinary management guideline with a 
section on quality of life,(3) and a related document which discussed briefly quality of life 
questionnaire options, and described a recommended measure, the University of Washington 
quality of life questionnaire (UW-QOL v4).(2)  There is, however, no mention of the measure in the 
ŵĂŶĂŐĞŵĞŶƚ ŐƵŝĚĞůŝŶĞ ? ƚŚŽƵŐŚ Ă ƌĞĨĞƌĞŶĐĞ ƚŽ ŝƚ ŝƐ ŐŝǀĞŶŝŶ ƚŚĞ  ?ĨƵƌƚŚĞƌ ƌĞĂĚŝŶŐ ? ƐĞĐƚŝŽŶ. Lowe & 
Rogers give no detail or background to their document, but it would appear that it is published by 
BAHNO, and can therefore assume endorsement.(2)  
 
Lowe & Rogers state that there will be no perfect head and neck questionnaire, and cite a 2001 
structured review of quality of life measures in head and neck cancer patients.(9) They also state 
 ?ƚŚĞƌĞŝƐĂĐŚŽŝĐĞďĞƚǁĞĞŶĂďŽƵƚ ? ?ǀĂůŝĚĂƚĞĚŵĞĂƐƵƌĞƐ ? ?ĐŝƚŝŶŐƚŚĞƐĂŵĞ ? ? ? ?ƌĞǀŝĞǁĂŶĚĂ ? ? ? ?
review.(10) They cite EORTC (European Organisation for Research and Treatment of Cancer), FACT 
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(Functional Assessment of Cancer Therapy) and UW-QOL as the most commonly used measures, but 
prefer the UW-QOL v4 for its brevity and suitability for routine clinical practice.  
 
Whilst the recommendation comes from a recognised professional body, there is no description of 
how the decision was reached, and no psychometric evaluation is in evidence. The document is also 
now somewhat out of date, having been published in 2008, and being largely based on a structured 
review conducted in 1999. Notably, a module specific to head and neck cancer (quality of life 
questionnaire head and neck 35 (QLQ-H&N35)) was developed to be used in conjunction with the 
EORTC QLQ-C30 at around the same time.(11) A brief search identified a systematic review of the 
psychometric properties of the QLQ-H&N35, published in 2013,(12) and which reported that 
construct validity and responsiveness had been rarely formally investigated, but that other 
psychometric properties were robust. They also reported that there was some room for 
improvement of the instrument in terms of methodological issues such as low internal consistency 
of some multi-item scales, and poor compliance of investigators in administering or reporting all 
scales within the tool.    
 
Based on the limited evidence that was identified on alternative measures, in keeping with the 
recommendations for the bowel cancer audit, it is recommended that the EQ-5D and the EORTC 
QLQ-C30 (plus the QLQ-H&N35 module) are collected in the NCA with a view to assessing the 
psychometric properties of the measures using the NCA data (see Section 4.4). 
 
 
4.3 Evidence for economic evaluations in head and neck cancer (WP1.3) 
4.3.1 Cost-effectiveness modelling approach used in recent HTAs in head and neck cancer 
Two single technology appraisals (STAs) relating to head and neck cancer were identified from the 
searches.(13;14)  Both technology appraisals (TAs) examined the clinical and cost-effectiveness of a 
pharmaceutical intervention plus radiotherapy compared to radiotherapy alone in patients with 
recurrent and/or metastatic head and neck cancer,(14) or patients with locally advanced squamous 
cell carcinoma of the head and neck.(13) 
 
State transition models were used to examine the cost-effectiveness of the interventions under 
appraisal.  Both models consisted of discrete health states which represented the clinical pathway 
for people with head and neck cancer at the point of the intervention (Table 1).  One STA restricted 
the number of health states to three (stable, progression, death) with progression defined as: a 25% 
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or more increase in the sum of the perpendicular dimensions of the index lesions compared to the 
smallest recorded in the study period, or the appearance of one or more new lesions, or uniquovocal 
progression of existing non-index lesions.(14)  The second STA included additional health states for 
treatment toxicities (Table 1, Figure 1).(13)  Progression and death were modelled using survival 
curves derived from RCTs (see Figure 2 for exemplar). 
 
Figure 1: Modelling approach used in head and neck cancer HTAs 
 
Legend: Orange framed boxes with uppercase text describe the health states used in the head and neck cancer 
TA models while the purple framed boxes with lower case (plain) text describe the evidence used.  Italised text 
indicative of additional variables which would be informative for future economic evaluations in head and neck 
cancer. 
 
  
11 
 
Figure 2:  Exemplar survival curves used to model interventions in cancer 
 
PFS=Progression free survival 
 
Both studies quality adjusted survival by assigning mean utility values to the discrete health states.  
Presumably due to the lack of more appropriate evidence, neither study used preference-based 
utility values obtained from patients with head and neck cancer.  In the first study, proxy EQ-5D 
scores were obtained from a group of oncology nurses who were asked to judge how a patient with 
head and neck cancer would complete the EQ-5D questionnaire if they were experiencing particular 
sets of symptoms which included treatment toxicities such as grade 3 or 4 nausea and vomiting.(13)  
The second study used a published relationship to map from the European organisation for research 
and treatment of cancer core quality of life questionnaire (EORTC-QLQ) to the EQ-5D, using EORTC-
QLQ data collected in the study used to describe the clinical effect of the intervention.(14)  However, 
it must be noted that this was far from ideal as the data used to determine the relationship was 
obtained from patients with pancreatic cancer.   
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Table 1: Summary of existing models used in head and neck cancer TAs 
 Model approach Method used to model utilities  
STA (TA172): Head and neck cancer (squamous cell carcinoma)  ? cetuximab; 2009(14) 
 State transition model 
3 discrete health states: stable/response, 
progressive, death 
Effectiveness: survival curves 
Source: clinical studies 
Utility: mapping EORTC QLQ-C30 to EQ-5D; mean 
values assigned to discrete HS 
Source: EORTC QLQ taken from RCT used for clinical 
effect (EXTREME trial); regression coefficients from 
people with pancreatic cancer -published literature   
AEs: assumed utility independent of treatment  
STA (TA145): Head and neck cancer - cetuximab; 2006(13) 
 State transition model  
10 discrete health states: loco regional 
control, progressive disease, death, general 
in- treatment, general in-treatment plus: 
mucositis grades 3 & 4, mucositis grade 2, 
haematological grade 4, nausea and 
vomiting grades 3&4, nausea and vomiting 
grade 2, acne rash grades 3&4 
Effectiveness: survival curves 
Source: clinical studies 
Utility: proxy EQ-5D scores; mean values assigned to 
discrete HS 
Source: Oncology nursing staff (n=50) were given pre-
defined health states relevant to head and neck 
cancer and asked to use their judgement on how a 
patient would complete the EQ-5D for each of these. 
Preference-based values then calculated using normal 
UK preference weights. 
AEs: described by the HS used 
HS: health states; AE: Adverse Events; STA: Single Technology Appraisal; TA: Technology Appraisal; RCT: 
randomised controlled trial; EORTC QLQ: European organisation for research and treatment of cancer core 
quality of life questionnaire. 
 
 
 
In summary, the following evidence would be required to compare providers or the cost-
effectiveness of interventions for head and neck cancer: 
 
x Condition severity  
x Pharmaceutical interventions (type of intervention, concomitant medications, remission 
rates, relapse rates, adverse events) 
x Progression measured using lesion(s) location and sizes 
x Utility values 
x Death with cause  
 
The majority of this evidence would need to be linked through timings of collection.  
 
 
4.3.2 Fields collected in the head and neck cancer NCA  
The head and neck cancer audit collects data from hospitals in eligible trusts which diagnose and 
treat patients with cancer of the larynx and oral cavity (excludes tumours of the brain and thyroid 
cancers) in England and Wales.  The fields in the head and neck cancer NCA are collected via an excel 
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spreadsheet completed by NHS staff. It is not clear which fields (if any) are mandatory (Appendix).  
The data collected relate to the first round of treatment during the clinical audit period, although 
additional multi-disciplinary team (MDT) records are included for each primary tumour.  The fields 
provide information on patient characteristics (date of birth, name, postcode, gender, date of 
death); MDT discussion (clinical history, tests and results, tumour site, agreed care plan, recurrence 
indicator and date), surgery (provider, procedure code group and date, discharge date or death 
before discharge, pathological tumour site category, unscheduled return to surgery for same 
primary operation), non-surgical intervention (provider, date, type, radiotherapy, chemotherapy), 
palliative and nursing care, referral to speech and language therapists (SaLT), clinical status (primary 
tumour, nodes, metastasises), and nutrition. 
 
 
4.3.3 Comparing fields in head and neck cancer NCA with variables used in existing HTAs  
The existing models in head and neck cancer use survival curves for progression free survival and 
overall survival (OS).  The information on clinical interventions (tumour, treatment, follow-up, 
Appendix) collected in the NCA would provide some of the information required to compare 
alternative treatments.  The mortality data could be used to model overall mortality, and there may 
be sufficient detail to extract survival curves for progression and recurrence.  It may also be possible 
ƚŽƵƐĞƚŚĞ ?ƌĞĐƵƌƌĞŶĐĞŝŶĚŝĐĂƚŽƌ ?ĨŽƌƌĞůĂƉƐĞ ?Side-effects and adverse events due to chemotherapy, 
radiotherapy and surgery are prevalent.  While there is some information on unscheduled return to 
surgery for the primary operation, there do not appear to be any fields relating to toxicity from 
chemotherapy or adverse effects of radiotherapy.   
 
Patient related outcome measures are not currently collected in the head and neck cancer NCA.  The 
inclusion of a preference-based HRQoL questionnaire such as the EQ-5D (alongside a condition 
specific measure such as the EORTC), would be useful for future economic evaluations, particularly 
as the existing HTAs do not in general use preference-based data to weight survival due to a dearth 
of evidence in patients with head and neck cancer.  There are no variables collected in the audit 
which could be used to generate proxy HRQoL values through an established relationship due to the 
paucity of evidence on HRQoL in this population. 
 
Assuming the fields have relatively high completion rates, with the exception of HRQoL, and 
toxicity/side effects of interventions, the information currently collected in the existing NCA may 
provide the majority of information required to model the cost-effectiveness of interventions and 
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policies in head and neck cancer.  As previously noted, there is a dearth of preference-based HRQoL 
evidence in head and neck cancer, and the collection of a preference-based measure within the NCA 
would be recommended as an important and valuable consideration.  It is understood that a 
feasibility study is scheduled sometime during the next couple of years, and it is possible that the 
new contract will include the collection of PROMs when the head and neck cancer NCA undergoes a 
retendering process later this year (2014).[personal communication, Eleanor Bunn, Audit 
Coordinator, 13th May 2014; personal communication, Julie, DAHNO Health And Social Care 
Information Centre, 10th July 2014] 
 
 
4.4 Recommendations for head and neck cancer  
The searches conducted to identify evidence on the appropriateness of the EQ-5D found no relevant 
studies.  Although relatively old (2006 and 2009), the two TAs in head and neck cancer 
demonstrated that there were substantial gaps in the evidence base used to assign HRQoL scores 
along the clinical pathway for patients with head and neck cancer.  The data used in these TAs do 
not satisfy the requirements of a submission to the NICE.  The estimated, assumed, and predicted 
proxy utility scores increase the uncertainty in results generated from models.  While it is likely that 
with exceptions, the current head and neck cancer audit collects much of the evidence needed to 
perform economic evaluations, this is far from clear.  In addition, the head and neck audit is 
completed by clinicians/NHS staff and does not currently include a patient completed component.  
Potential recommendations (PR) and areas for future research (FR) are discussed below.  All 
suggested future research areas are indicative and would require a discussion and detailed proposal 
if required.   
 
It is clear that this is an area where research is required to inform the most appropriate PROM.  The 
primary recommendation would be to consider collecting PROMs in this population, either through a 
postal questionnaire or electronically at strategic points in the care pathway (PR.1).  It is 
recommended that the EQ-5D is considered for inclusion in the first instance to enable the evidence 
to be used to generate quality adjusted life years (QALYs) in economic evaluations.  However, 
research would be required to determine the appropriateness of the EQ-5D in this population (FR.1), 
and it is recommended that a condition specific measure (such as the EORTC QLQ-C30 together with 
the QLQ-H&N35 module) is collected alongside the EQ-5D (PR.2).   
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Adverse events and side-effects of chemotherapy and surgical/radiotherapy interventions are 
prevalent and are key variables when assessing the benefits of interventions and procedures used in 
in cancer.  It is recommended that these are included as mandatory variables in future audits (PR.3).  
It is also recommended that an appropriate measure of severity (such as mucositis grade) is 
collected alongside changes in lesions (PR.4).   
 
Table 2: Recommendations and associated future research for head and neck cancer 
PR.1 Include a patient questionnaire or the provision for electronic collection of PROMs 
PR.2 Include the EQ-5D in future patient questionnaires alongside a condition specific measure 
such as the EORTC QLQ-C30 and the QLQ-H&N35 module 
FR.1 Assess the psychometric properties of the EQ-5D using the data collected in the head and 
neck cancer NCA 
PR.3 Information on adverse events associated with chemotherapy regimens and the side effects 
of surgical interventions and radiotherapy 
PR.4 Collect an appropriate measure of severity, such as mucositis grade alongside information 
on lesions 
PR.5 Include additional mandatory fields in the head and neck cancer audit 
FR.2 Detailed analyses of fields currently collected in the head and neck cancer audit to identify 
recommendations for future mandatory fields 
 
 
 
5.  SUMMARY   
5.1 Summary of evidence used to inform the conclusions for WP1.1 and WP1.2 
One review was identified and an update search conducted. No primary research studies relating to 
the psychometric properties of the EQ-5D in head and neck cancer were identified. Searches 
identified seven published clinical or research guidelines relating to other measures, but none of 
these were based on up to date evidence. Given the limited evidence available, it is recommended 
that the EQ-5D is used alongside the EORTC QLQ-C30 and head and neck specific module, the QLQ-
H&N35, in keeping with the recommendations for bowel cancer (Table 3). 
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Table 3: Summary of evidence currently available for recommended measure(s) 
Condition N Acceptability Reliability Construct Responsiveness Overall 
KGV Convergent Change  
over 
time 
Ceiling  
Effect 
EQ-5D 0 NE NE NE NE NE NE No evidence 
Head and 
Neck 
Cancer 
EORTC QLQ-
C30 
EORTC QLQ-
H&N35 
 The psychometric properties of these measures have not been reviewed in 
the current report 
N= number of studies used to inform conclusions, KGV: known group validity; NE, no evidence was identified  
 
 
5.2 Summary of evidence required for use in economic evaluations (WP1.3) 
The head and neck cancer audit does not include a patient questionnaire thus PROMs are not 
currently collected and there does not appear to be an alternative field which could be used to 
predict the required preference-based utility values.  Assuming there is a relatively high completion 
rate, it is thought that this audit collects much of the information required to derive survival curves 
for progression and recurrence of the disease but again key information may be missing such as 
condition severity (measured using information of lesions and required to case-mix when comparing 
providers), current pharmaceutical interventions (type of intervention, concomitant medications, 
remission rates, relapse rates, adverse events), surgical rates and complications. 
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APPENDIX: HEAD AND NECK CANCER 
The tables in this Appendix provide additional information for the reviews (WP1.1, 1.2 and 1.3) conducted for 
head and neck cancer.   There are no tables for WP1.1 as no evidence was identified. 
 
Table A1: Mandatory fields collected in the head and neck cancer NCA  
PATIENT
 
 Date of birth, Postcode, Gender, Date of death 
MDT DISCUSSION
 
 Has patient had a pre treatment nutrition assessment, Year symptoms first noted, Chest XR performed 
prior to treatment, CT chest performed prior to treatment, , CT Primary / Neck performed prior to 
treatment, MRI primary performed prior to treatment, PET CT scan performed prior to treatment, 
Orthopantomogram (OPG) performed prior to treatment, Ultrasound performed prior to treatment, 
Biopsy procedure date, Date pathology report, Tumour laterality, Date of diagnosis, Primary site group, 
Primary site, Basis of diagnosis, Histological diagnosis at biopsy, First diagnosis organisation, Has HPV 
Status testing been done, HPV Test, HPV status, MDT organisation, Referral for cancer decision date, Has 
patient been discussed at MDT, MDT discussion date, Comorbidity index, Performance status, Care plan 
agreed date, Cancer care plan intent, Planned cancer treatment type 1, Planned cancer treatment type 2, 
Planned cancer treatment type 3, Planned cancer treatment type 4, Final Pre-treatment tumour site T 
Category, Final pre-treatment tumour site N Category, Final pre-treatment tumour site M Category, Has 
patient had a pre treatment nutrition assessment, Has patient had a pre treatment dental  assessment, 
Recurrence indicator, Date of recurrence 
SURGERY
 
 Surgery provider organisation, Cancer treatment intent, Procedure date, Procedure code group 1, 
Procedure code 1, GMC 1, Procedure code group 2, Procedure code 2, GMC 2, Procedure code group 3, 
Procedure code 3, GMC 3, Procedure code group 1, Procedure code 4, GMC 4, Procedure code group 5, 
Procedure code 5, GMC 5, Procedure code group 6, Procedure code 6, GMC 6, "Did the patient die prior 
to discharge?", Discharge date, Date of post-resective pathology report, Post-resective histological 
diagnosis, Pathological tumour site T category, Pathological tumour site N category, Pathological tumour 
site M category, Was resective pathology discussed at MDT, Was there an unplanned return to theatre 
during the same admission for same primary operation? 
NON SURGICAL
 
  Treatment provider organisation, Treatment start date, Treatment type, Cancer treatment intent, 
Radiotherapy treatment to, Chemotherapy drug type 
PALLIATIVE, NURSING AND SaLT
 
  Palliative care organisation, Palliative care start date,  
Nursing care organisation, First CNS contact date, CNS present when patient advised of diagnosis, Has a 
patient concerns inventory been carried out? 
SaLT care organisation, First SaLT date, Was this patient assessed post treatment, Normalcy of diet (pre-
treatment), Normalcy of diet at 3 months, Normalcy of diet at 12 months, Laryngectomy proposed 
method of post operative communication, Laryngectomy communication method (3 months post op), 
Laryngectomy communication method (12 months post op) 
STATUS 
  Status recording organisation, Clinical status assessment date, Primary tumour status, Nodal status, 
Metastatic status 
NUTRITION 
  Nutritional care organisation, Contact date (Dietician initial), Was the patient nutritionally assessed within 
1 month of treatment, What was the predominant method of nutritional support during treatment, What 
was the predominant tube type used during treatment, Was patient seen within 6 weeks of completion 
of treatment? 
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